Financhill
Sell
40

NURO Quote, Financials, Valuation and Earnings

Last price:
$4.39
Seasonality move :
-5.57%
Day range:
$4.35 - $4.43
52-week range:
$2.66 - $4.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.04x
P/B ratio:
0.56x
Volume:
4.9K
Avg. volume:
7.8K
1-year change:
14.73%
Market cap:
$9M
Revenue:
$5.9M
EPS (TTM):
-$4.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NURO
NeuroMetrix
-- -- -- -- --
CATX
Perspective Therapeutics
$267.3K -$0.25 -- -41.72% $15.58
ECOR
electroCore
$7.1M -- 25.79% -- $25.20
VNRX
VolitionRX
$545.3K -$0.05 123.53% -51.52% $3.37
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.8M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NURO
NeuroMetrix
$4.41 -- $9M -- $0.00 0% 2.04x
CATX
Perspective Therapeutics
$2.60 $15.58 $175.7M -- $0.00 0% 14.04x
ECOR
electroCore
$8.26 $25.20 $59.4M -- $0.00 0% 2.45x
VNRX
VolitionRX
$0.57 $3.37 $52.8M -- $0.00 0% 36.80x
VTAK
Catheter Precision
$0.41 -- $3.3M 0.47x $0.00 0% 1.09x
XTNT
Xtant Medical Holdings
$0.48 $1.75 $66.8M -- $0.00 0% 0.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NURO
NeuroMetrix
-- 0.088 -- 12.38x
CATX
Perspective Therapeutics
-- -3.661 -- --
ECOR
electroCore
-- -2.016 -- 1.46x
VNRX
VolitionRX
-28.76% -0.785 8.83% 0.19x
VTAK
Catheter Precision
12% -2.395 128.21% 0.53x
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NURO
NeuroMetrix
$312K -$1.7M -41.7% -41.7% -296.61% -$1.8M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
ECOR
electroCore
$6.1M -$3.1M -147.07% -147.07% -43.59% -$1.3M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

NeuroMetrix vs. Competitors

  • Which has Higher Returns NURO or CATX?

    Perspective Therapeutics has a net margin of -256.8% compared to NeuroMetrix's net margin of --. NeuroMetrix's return on equity of -41.7% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About NURO or CATX?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 8979.15%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 499.11%. Given that NeuroMetrix has higher upside potential than Perspective Therapeutics, analysts believe NeuroMetrix is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is NURO or CATX More Risky?

    NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock NURO or CATX?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or CATX?

    NeuroMetrix quarterly revenues are $587.3K, which are larger than Perspective Therapeutics quarterly revenues of --. NeuroMetrix's net income of -$1.5M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 14.04x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    2.04x -- $587.3K -$1.5M
    CATX
    Perspective Therapeutics
    14.04x -- -- -$15.1M
  • Which has Higher Returns NURO or ECOR?

    electroCore has a net margin of -256.8% compared to NeuroMetrix's net margin of -45.81%. NeuroMetrix's return on equity of -41.7% beat electroCore's return on equity of -147.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    ECOR
    electroCore
    85.89% -$0.40 $7.5M
  • What do Analysts Say About NURO or ECOR?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 8979.15%. On the other hand electroCore has an analysts' consensus of $25.20 which suggests that it could grow by 205.09%. Given that NeuroMetrix has higher upside potential than electroCore, analysts believe NeuroMetrix is more attractive than electroCore.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    ECOR
    electroCore
    3 0 0
  • Is NURO or ECOR More Risky?

    NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison electroCore has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.612%.

  • Which is a Better Dividend Stock NURO or ECOR?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or ECOR?

    NeuroMetrix quarterly revenues are $587.3K, which are smaller than electroCore quarterly revenues of $7M. NeuroMetrix's net income of -$1.5M is higher than electroCore's net income of -$3.2M. Notably, NeuroMetrix's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 2.45x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    2.04x -- $587.3K -$1.5M
    ECOR
    electroCore
    2.45x -- $7M -$3.2M
  • Which has Higher Returns NURO or VNRX?

    VolitionRX has a net margin of -256.8% compared to NeuroMetrix's net margin of -1226.82%. NeuroMetrix's return on equity of -41.7% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About NURO or VNRX?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 8979.15%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 491.71%. Given that NeuroMetrix has higher upside potential than VolitionRX, analysts believe NeuroMetrix is more attractive than VolitionRX.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    VNRX
    VolitionRX
    2 1 0
  • Is NURO or VNRX More Risky?

    NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

  • Which is a Better Dividend Stock NURO or VNRX?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or VNRX?

    NeuroMetrix quarterly revenues are $587.3K, which are larger than VolitionRX quarterly revenues of $474.5K. NeuroMetrix's net income of -$1.5M is higher than VolitionRX's net income of -$5.8M. Notably, NeuroMetrix's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 36.80x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    2.04x -- $587.3K -$1.5M
    VNRX
    VolitionRX
    36.80x -- $474.5K -$5.8M
  • Which has Higher Returns NURO or VTAK?

    Catheter Precision has a net margin of -256.8% compared to NeuroMetrix's net margin of -4291.67%. NeuroMetrix's return on equity of -41.7% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About NURO or VTAK?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 8979.15%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 387.69%. Given that NeuroMetrix has higher upside potential than Catheter Precision, analysts believe NeuroMetrix is more attractive than Catheter Precision.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is NURO or VTAK More Risky?

    NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

  • Which is a Better Dividend Stock NURO or VTAK?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or VTAK?

    NeuroMetrix quarterly revenues are $587.3K, which are larger than Catheter Precision quarterly revenues of $96K. NeuroMetrix's net income of -$1.5M is higher than Catheter Precision's net income of -$4.1M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 1.09x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    2.04x -- $587.3K -$1.5M
    VTAK
    Catheter Precision
    1.09x 0.47x $96K -$4.1M
  • Which has Higher Returns NURO or XTNT?

    Xtant Medical Holdings has a net margin of -256.8% compared to NeuroMetrix's net margin of -10.04%. NeuroMetrix's return on equity of -41.7% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About NURO or XTNT?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 8979.15%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that NeuroMetrix has higher upside potential than Xtant Medical Holdings, analysts believe NeuroMetrix is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is NURO or XTNT More Risky?

    NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

  • Which is a Better Dividend Stock NURO or XTNT?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or XTNT?

    NeuroMetrix quarterly revenues are $587.3K, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. NeuroMetrix's net income of -$1.5M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    2.04x -- $587.3K -$1.5M
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock